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Abstract
Background: In high-income countries, allergy-related diseases (ARDs) follow a
typical sequence, the ‘Atopic March’. Little is known about the life-course of ARDs in
the markedly different, low-income, tropical environment. We describe ARDs in a
tropical, African birth cohort.
Methods: Ugandan children were followed from birth to 9 years. ISAAC question-
naires were completed at intervals; doctor-diagnosed ARDs were recorded throughout
follow-up. Skin prick tests (SPTs) were performed at 3 and 9 years. Atopy was defined
as ≥1 positive SPT.
Results: Of the 2345 live-born children, 1214 (52%) were seen at 9 years. Wheeze and
eczema were common in infancy, but by 9 years, only 4% reported recent wheeze, 5%
eczema and 5% rhinitis. Between 3 and 9 years, atopy prevalence increased from 19%
to 25%. Atopy at 3 or 9 years was associated with reported ARD events at 9 years, for
example OR = 5.2 (95% CI 2.9–10.7) for atopy and recent wheeze at 9 years.
Reported or doctor-diagnosed ARD events in early childhood were associated with
the same events in later childhood, for example OR = 4.4 (2.3–8.4) for the association
between reported wheeze before 3 years with reported recent wheeze at 9 years, but
progression from early eczema to later rhinitis or asthma was not observed.
Conclusion: Allergen sensitization started early in childhood and increased with age.
Eczema and wheeze were common in infancy and declined with age. Atopy was
strongly associated with ARD among the few affected children. The typical Atopic
March did not occur. Environmental exposures during childhood may dissociate
atopy and ARD.
Allergy-related diseases (ARDs, such as asthma, eczema and
rhinitis) affect approximately 20% of the world’s population
(1). Asthma affects nearly 300 million people (2) and eczema
15–30% of all children (3). Although ARDs have been
uncommon in low- and middle-income countries (LMIC),
recent literature suggests they are increasing (4).
Atopy (defined by elevated allergen-specific immunoglobulin
E [asIgE] or skin prick test [SPT] positivity to common
allergens) is associated with ARDs in high-income countries
(HICs) (5), but a heterogeneous picture is described in LMICs
(5, 6), suggesting coexistence of atopic and non-atopic ARD
(7).
In HICs, eczema is usually the first presentation in the
sequential manifestation of ARDs, and often lessens by age
4 years, when asthma and/or allergic rhinitis emerge, a
transition known as the ‘Atopic [or Allergic] March’ (1). Early
atopic sensitization is linked to the subsequent development of
ARDs (8). However, little is known about the life-course of
ARDs in low-income tropical environments, which differ from
HICs in many aspects of lifestyle and the intensity of exposure
to infections, especially chronic parasitic infections.
The Entebbe Mother and Baby Study (EMaBS) is a birth
cohort, initially designed to investigate whether anthelminthic
treatment in pregnancy and early childhood influences
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children’s response to vaccines and infections (9). Helminths
and anthelminthic treatment showed only modest effects on
infants’ response to vaccines (10, 11), but hookworm infection
in pregnancy was inversely associated with childhood eczema
(12), and anthelminthic treatment in pregnancy increased the
incidence of infantile (13) and childhood eczema (14). We
describe the prevalence, phenotype, severity, inter-relationships
and life-course of ARD events among children in this tropical
birth cohort, to age 9 years.
Methods
Study population
The EMaBS is based in Entebbe municipality and Katabi
subcounty, Wakiso district, Uganda: a peninsula on Lake
Victoria, comprising urban, rural and fishing communities.
Study design
Between 2003 and 2005, pregnant women were recruited into a
randomized, double-blind, placebo-controlled trial of anthel-
minthic treatment in pregnancy and early childhood, and
followed up as previously described [ISRCTN32849447] (9).
The Research and Ethics Committee of the Uganda Virus
Research Institute, the Uganda National Council for Science
and Technology, and the London School of Hygiene and
Tropical Medicine granted ethical approval.
Investigation of allergy-related disease outcomes
At ages 1, 2, 3, 5 and 9 years, caregivers were interviewed (in
the child’s presence) on ARD symptoms using questions from
the International Study on Allergy and Asthma in Children
(ISAAC) questionnaire (15) and data on urticaria were also
collected. For data collected at age 3 years, these questions
were included in the questionnaire from November 2007
onwards; hence, only responses from children attending their
age 3 visit from that date onwards were collected.
Reported recent events were wheeze, eczema (a recurrent
pruritic rash with typical infant or child distribution), allergic
rhinitis (sneezing or runny nose or blocked nose, with itchy and
watery eyes, without having a cold or ‘flu’) and urticaria
(pruritic rash with wheals, ‘ebilogologo’ in the vernacular),
occurring in the preceding 12 months.
At 9 years, the questionnaire was supplemented with (i) the
ISAAC video questionnaire (VQ; shown after the oral ques-
tionnaire [OQ]), and (ii) questions from the UK diagnostic
criteria (UKDC) for atopic eczema (15). The VQ contained five
short sequences of asthma symptoms (audible wheezing with-
out breathlessness, exercise-induced wheezing, waking at night
with breathlessness, nocturnal coughing, a severe asthma
attack). Each sequence was followed by questions asking
whether the child’s breathing had ‘ever’ or ‘in the last
12 months’ been like the person’s in the video. Children were
examined for visible flexural dermatitis by team members
trained in the standardized approach (16). The UKDC defines
eczema as a recent pruritic rash with at least three of the
following: history of flexural involvement, history of generally
dry skin, personal history of asthma or allergic rhinitis, visible
flexural dermatitis and onset below age 2 years.
Doctor-diagnosed ARD events were identified when sick
children presented to the study clinic. Wheezing episodes below
the age of 5 years were documented. Asthma was diagnosed
after the age of 5 years as an episode of wheezing or, a dry
nocturnal cough, with a previous asthma-like episode, after
excluding other possible causes. Eczema was a recurrent
pruritic rash lasting more than 6 months, with typical infant
or child distributions.
Atopic sensitization
Skin prick testing was performed in a subset of three-year-olds
(those who attained 3 years of age from November 2007
onwards, when SPT was added to the procedures performed at
this visit) and in nine-year-olds, on the volar surface of the arm
using standard methods (17) with allergens likely to elicit a
response in this setting (18). At 3 years (12), dust mites
(Dermatophagoides, Blomia tropicalis), cow’s milk and egg
white were used; and at 9 years, the dust mites, German
cockroach (Blattella germanica), peanut, Bermuda grass, cat,
pollen and mould were used (ALK-Abello, Laboratory Spe-
cialities (Pty) Ltd, Randburg, South Africa). Wheals were
measured after 15 min, positive being a mean diameter ≥3 mm.
The primary definition of atopy was SPT positivity to at
least one allergen (further categorized as monosensitivity
[sensitive to one allergen] and polysensitivity [≥2 allergens]).
At 9 years, plasma stored at 80°C was assessed for
Dermatophagoides-specific (Der-p) IgE response using an in-
house ELISA as previously described (13). The lower detection
limit was 312 ng/ml. A secondary definition of atopy was
detectable Der-p IgE >312 ng/ml.
Statistical analysis
Data were double-entered in Microsoft Access and analysed
with Stata 14 (College Station, TX, USA). Chi-square tests
were used to compare maternal baseline (age, education,
marital status, any worm infection, body mass index, anaemia)
and child (sex, atopy at 3 years and infantile eczema diagnosis)
characteristics between children seen and not seen at age
9 years. Agreement between OQ and VQ was determined by
kappa statistic (j) (19).
Cross-sectional associations between atopy and reported
recent ARD events at 9 years were estimated using logistic
regression and population-attributable fraction (PAF) calcu-
lated. Longitudinal inter-relationships between atopy or
reported ARDs in the first 3 years of life (reported ARD
event at 1, 2 or 3 years) and atopy or reported ARDs at 9 years
were examined using logistic regression. Poisson regression
with random effects was used to assess whether reported ARDs
or doctor-diagnosed ARD events in early childhood
(0–5 years) or atopy at 3 years were associated with
doctor-diagnosed ARD events between 5 and 9 years.
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Results
Of the 2345 live births, 1214 (52%) children were seen at
9 years. Fig. 1 shows the number of participants seen at each
annual visit (1, 2, 3, 5 and 9 years) and the number for whom
outcome data were collected at each time point. Of the nine-
year-olds, 626 (52%) were males, 1203 (99%) underwent SPT,
and 1140 (94%) had Der-p IgE measured. Children seen at
9 years were similar to those not seen in terms of some
maternal characteristics (marital status, BMI and worm
infection at enrolment), child’s sex, eczema diagnosis (before
age 1 year) and atopy (3 years). On average, children seen at
9 years had older, better educated mothers from households
with higher socio-economic status at enrolment.
Prevalence and life-course of ARD outcomes and atopy
Reported recent wheeze and eczema were most prevalent at
1 year and decreased with age. Reported recent urticaria
increased and was the most prevalent reported event by
9 years. Allergic rhinitis was rare throughout childhood
(Fig. 2).
At 9 years, by OQ, prevalence of recent wheeze was 3.8%,
eczema 4.9%, allergic rhinitis 4.6% and urticaria 15.5%
(Table 1). Of the 44 children with recent wheeze, 16 (36%)
had suffered ≥4 attacks in the last 12 months, 12 (27%)
reported speech interruption and 14 (32%) sleep disturbance.
Fifteen children (1.3%) reported recent eczema based on the
UKDC; of these 13 (87%) had their first episode before age
2 years. Of the 52 with allergic rhinitis, 9 (17%) reported
interruptions in daily activities.
Positive responses to the VQ were less common than to
the OQ (Table 1). Comparing OQ and VQ, agreement was
97%, j = 0.27, for recent wheeze vs. the scene showing
audible wheezing without breathlessness: 98%, j = 0.55, for
exercise-induced wheeze and 91%, j = 0.40, for nocturnal
coughing.
Between 5 and 9 years, rates of doctor-diagnosed events
were 8.2/1000 person-years (pyr) for asthma, 10.8/1000 pyr for
eczema and 9.3/1000 pyr for urticaria.
Live births (N = 2345)
Age1 y (N = 1722, 73%)
Age 2 y (N = 1586, 67%)
Age 5 y (N = 1434, 61%)
Age 9 y (N = 1214, 52%)
Allergic rhinis (N = 1716)
Age 3 y (N = 1533, 65%)
Eczema (N = 1715)
Wheeze (N = 1716)
Urcaria (N = 1705)
Allergic rhinis (N = 628)
Eczema (N = 628)
Wheeze (N = 629)
Urcaria (N = 623)
Allergic rhinis (N = 1561)
Eczema (N = 1562)
Wheeze (N = 1555)
Urcaria (N = 1553)
Allergic rhinis (N = 1324)
Eczema (N = 1321)
Wheeze (N = 1322)
Urcaria (N = 1315)
SPT (N = 569)
Allergic rhinis (N = 1141)
Eczema (N = 1179)
Wheeze (N = 1170)
Urcaria (N = 1165)
SPT (N = 1170)
ELISA (N = 1140)
Figure 1 Flow chart showing number of the Entebbe Mother and Baby Study participants seen at each time point and those providing outcome
information at each time point.
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The commonest SPT responses were to dust mites at both 3
and 9 years (Table 1; Fig. 3). As previously described (12), 569
children underwent SPT at 3 years of age, of whom 105 (18%)
were atopic, 11% positive for Dermatophagoides and 12%
positive for Blomia tropicalis.
At 9 years, SPT data from 33 participants were excluded;
three were excluded because saline (negative control) response
was ≥3 mm and 30 were excluded because histamine (positive
control) response was <3 mm. Thus, SPT results for at least
one allergen were available from 1170 children. Overall, 25%
of children were positive for at least one allergen, 18%
positive for Dermatophagoides, 15% to Blomia and 12% to
German cockroach. Polysensitivity was detected among 9% at
3 years and 15% at 9 years. Sensitivity to food allergens,
pollen or mould was uncommon at three or 9 years (Fig. 3).
There were 335 (29%) nine-year-olds with detectable Der-p
IgE.
Associations between atopy and reported ARD events at
9 years
Skin prick test positivity was associated with all reported recent
ARDs at 9 years (Table 2 (i)), with the strongest associations
seen for wheeze and allergic rhinitis (PAF = 52.1% and 72.2%,
respectively). Polysensitivity at 9 years was also associated with
wheeze (OR = 7.4, 95% CI: 3.9–13.9), eczema (OR = 3.2, 95%
CI: 1.8–5.7), allergic rhinitis (OR = 10.6, 95% CI: 5.8–19.2)
and urticaria (OR = 2.6, 95% CI: 1.8–3.9). Atopy defined by
detectable Der-p IgE showed similar, but weaker, associations
(Table 2 (ii)).
Among reported recent events at 9 years, wheeze was
associated with eczema (OR = 4.0, 95% CI: 1.7–9.4) and with
allergic rhinitis (OR = 10.5, 95% CI: 5.0–22.0). Urticaria was
associated more weakly with wheeze, eczema or allergic rhinitis
(OR, 95% CI: 2.6 (1.3–5.1), 1.9 (1.0–3.5) and 2.1 (1.1–4.0),
respectively).
Figure 2 Proportion of children with reported recent allergy-related
events by age in the Entebbe Mother and Baby Study cohort. Note:
missing data for given events at Year 1: eczema 1, urticaria 11; Year
2: wheeze 7, allergic rhinitis 1, urticaria 9; Year 3: eczema 1, allergic
rhinitis 1, urticaria 6; Year 5: wheeze 2, eczema 3, urticaria 9; Year 9:
wheeze 9, allergic rhinitis 38, urticaria 14.
Table 1 Allergy-related outcomes at 9 years of age in the Entebbe
Mother and Baby Study birth cohort
Allergic symptoms Present Absent
Prevalence
(95% CI)
Oral questionnaire responses
Asthma symptoms
Wheeze ever 75 1095 6.4% (5.1–8.0)
Reported recent
wheeze
44 1126 3.8% (2.7–5.0)
Reported recent
exercise-induced
wheeze
19 916 2.0% (1.2–3.2)
Reported recent dry
cough at night
108 829 11.5% (9.6–13.7)
Eczema
Reported recent
eczema
58 1121 4.9% (3.8–6.3)
Reported recent
eczema – UKDC
15 1161 1.3% (0.7–2.1)
Allergic rhinitis
Allergic rhinitis ever 52 1089 4.6% (3.4–5.9)
Reported recent
allergic rhinitis
52 1089 4.6% (3.4–5.9)
Urticaria
Urticarial rash ever 261 912 22.3% (19.9–24.7)
Reported recent
urticarial rash
180 985 15.5% (13.4–17.7)
Video questionnaire responses
Wheeze
Recent audible
wheeze at rest
13 1161 1.1% (0.6–1.9)
Recent exercise-
induced wheeze
22 1150 1.9% (1.2–2.8)
Recent waking at night
with wheeze
11 1159 0.9% (0.5–1.7)
Recent nocturnal
coughing
54 1109 4.6% (3.5–6.0)
Recent wheeze with
speech disturbance
14 1135 1.2% (0.7–2.0)
Skin prick test reaction
Atopy (any single
allergen)
292 867 25.2% (22.7–27.8)
Polysensitivity (≥2
positive allergens)
176 986 15.1% (13.1–17.3)
Dermatophagoides mix 210 958 18.0% (15.8–20.3)
Blomia tropicalis 174 989 15.0% (13.0–17.1)
German cockroach 128 1040 11.9% (9.2–12.9)
Peanut 16 1151 1.4% (0.8–2.2)
Bermuda Grass 14 1154 1.2% (0.7–2.0)
Cat 13 1151 1.1% (0.6–1.9)
Pollen 11 1155 0.9% (0.5–1.7)
Mould 3 1161 0.3% (0.1–0.8)
IgE to Dermatophagoides pteronyssinus
Detectable level 335 805 29.4% (26.8–32.1)
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Longitudinal associations between outcomes at 3 and 9 years
Atopy at 3 years was strongly associated with atopy at 9 years
and with reported ARD events (with the exception of urticaria)
at 9 years (Table S1). Reported recent wheeze or eczema before
3 years was weakly associated with atopy at 9 years (Table S2).
Children who reported a particular ARD event before 3 years
were more likely to report the same recent ARD event at
9 years, again with the exception of urticaria. However, there
was no evidence of association between reported eczema before
age 3 years and any of the other reported ARD outcomes at
9 years (Table S1).
Regarding doctor-diagnosed ARDs, children with a doc-
tor-diagnosed ARD before 5 years had higher rates of the
same ARD between 5 and 9 years (Table S2), but doctor-
diagnosed eczema before 5 years was not associated with
rates of other ARDs later in childhood (Table S2). Children
with atopy at 3 years had higher rates of asthma in later
childhood than those who were not atopic, but early atopy
was not associated with later rates of eczema or urticaria.
Associations between reported recent ARDs before 5 years
and doctor-diagnosed ARDs in later childhood showed
similar patterns (Table S2).
Discussion
This is the first description of the life-course of allergy-related
conditions in tropical sub-Saharan Africa. Eczema and wheeze
were common in infancy, but prevalence declined markedly by
3 years, and there was no increase in later childhood. By
contrast, atopic sensitization increased with age. However,
atopy was strongly associated with eczema, wheeze and
rhinitis, and these conditions were associated with each other.
Atopy or ARD in early life was associated with later ARD,
although the classic transition from eczema to rhinitis or
asthma (the ‘Atopic March’) was not observed. Reported
urticaria was an exception from this pattern: reported urticaria
increased with age and showed only weak associations with
atopy and other ARDs.
The strength of this study was the prospective collection of
data on doctor-diagnosed ARD throughout life, and of
reported events and SPT sensitivity at key intervals. A concern
was lack of familiarity among study participants and their
families with terms such as wheeze, asthma, eczema and
allergic rhinitis, which have no equivalents in the vernacular
(Luganda).
Moderate agreement between the OQ and VQ at age nine was
reassuring; the higher prevalence of wheeze by OQ may reflect
the more severe presentations of asthma shown in the VQ (20).
Figure 3 Trends in allergen sensitization, assessed by skin prick test
response, by age (year) in the Entebbe Mother and Baby Study
Cohort.
Table 2 Association between atopy and reported recent events
among nine-year-old children in the Entebbe Mother and Baby Study
birth cohort
Allergy-related
event
Atopy present
N (%)
OR
(95% CI)
PAF
(95% CI)
(i) Atopy defined by skin prick test response (at least one positive
SPT)
Wheeze
Absent 252/1066 (23.6) 1
Present 26 /41 (63.4) 5.6 (2.9–10.7) 52.1%
(41.7–57.5)
Eczema
Absent 251/1057 (23.8) 1
Present 29/58 (50.0) 3.2 (1.9–5.5) 34.4%
(23.4–40.9)
Allergic rhinitis
Absent 229/1028 (22.2) 1
Present 40/51 (78.4) 12.7 (6.4–25.1) 72.2%
(66.2–75.3)
Urticaria
Absent 214/934 (22.9) 1
Present 61/168 (36.3) 1.9 (1.4–2.7) 17.4%
(9.5–23.0)
(ii) Atopy defined by detectable allergen-specific IgE to
Dermatophagoides pteronyssinus
Wheeze
Absent 297/1046 (28.4) 1
Present 21/38 (55.3) 3.1 (1.6–6.0) 37.5%
(21.2–46.0)
Eczema
Absent 300/1038 (28.9) 1
Present 22/55 (40.0) 1.6 (0.9–2.9) 15.6%
(0.0–26.0)
Allergic rhinitis
Absent 275/1008 (27.3) 1
Present 32/49 (65.3) 5.0 (2.7–9.2) 52.3%
(41.5–58.2)
Urticaria
Absent 255/908 (28.1) 1
Present 61/171 (35.7) 1.4 (1.0–2.0) 10.6%
(0.2–17.9)
PAF, Population-attributable fraction.
Missing values for atopy (SPT): wheeze 62; eczema 64; allergic
rhinitis 62; urticaria 63.
Missing values for atopy (asIgE): wheeze 86; eczema 86; allergic
rhinitis 84; urticaria 86.
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Reported wheeze is not synonymous with asthma, even among
older children, but is regarded as the best tool for collection of
epidemiological data on asthma (21). The children retained in the
cohort at age 9 years, compared to those lost to follow-up, came
from relatively well-to-do families and as such are not fully
representative of the original study population. Also, SPT at age
3 yearswasonly performedona (chronological) subset of cohort
children due to study procedures being introduced when many
children had already attended their three-year annual visit.
However, rates of infantile eczema and prevalence of atopy at
3 years were similar between those seen at 9 years and those seen
as young children but later lost to follow-up, and prevalence of
ARDs at 9 years was similar among those who did and did not
have SPT results at age 3 years.
Urticaria is a well-recognized phenomenon, known in
Luganda as ‘ebilogologo’. Given the differing life-course of
reported urticaria, and weak associations with atopy, we
suspect that this represents a different phenomenon to other
ARDs, possibly the long-recognized response to active
helminth infections (22) or exposure to insect venoms,
increasing with age.
The prevalence of wheeze, eczema and rhinitis at 9 years in
this population was low in relation to global findings from the
ISAAC studies, which involved six- to seven-year-olds and 13-
to 14-year-olds in many countries. Our results, compared to the
ranges among younger and older participants at ISAAC
centres, respectively, were as follows: for recent wheeze 4%,
compared to 4–32% and 2–32% (23); for eczema 5% (1%
using the more rigorous UK diagnostic criteria), compared to
2–16% and 1–17% (24); for rhinitis 5%, compared to 2–65%
and 4–80% (25). In ISAAC populations, ARD prevalence
tended to be lower in less affluent and more rural centres, and
our findings accord with this pattern: EMaBS participants were
drawn from a mixed urban–rural setting, recruited at the
government hospital (an option usually chosen by less affluent
women), and 85% of women were earning less than £10 per
month at enrolment (26).
By contrast, we found a much stronger association between
ARDs and atopy (measured by skin prick test) than we
expected based on ISAAC. For wheeze, our point estimates for
OR (5.2 [95% CI: 2.9–10.7]) and PAF (52%) exceeded the
grouped estimate for ISAAC’s affluent countries (4.0 [3.5–4.6]
and 41%, respectively (5)); similarly, for eczema, our OR and
PAF estimates (3.2 [1.9–5.5] and 34%) exceeded ISAAC values
for affluent settings (2.7 [2.3–3.1] and 28% (27)). ISAAC’s
estimates for non-affluent settings were about half the values
for affluent countries, or lower. It is possible that these stronger
associations could be partially explained by underreporting of
ARDs in this setting, where directly translatable terms for
asthma, eczema and rhinitis are not available.
The concept of the ‘Atopic March’ suggests that an impaired
skin barrier (perhaps related to mutations in, for example, the
filaggrin gene) renders individuals susceptible to atopic sensi-
tization and thereafter vulnerable to atopic eczema and later to
atopic rhinitis and atopic asthma (1). Our data show that
atopic sensitization was acquired early and increased with age
among children in this population, to levels comparable to
affluent settings (28) and that early sensitization was associated
with later ARD. However, despite these findings, the vast
majority of children with early atopic sensitization, eczema or
wheeze had no evidence of ARD by age 9 years.
We, and others, have previously shown the importance of
early life (including prenatal) exposures in ARD risk (12, 29).
However, these new data suggest that environmental factors
experienced later in life can further dissociate acquired atopy
from ARD risk, thus preventing the Atopic March. Possible
candidates include immunomodulating infections such as
helminths and malaria, which are common in this setting. A
separate analysis of risk factors for ARD in this cohort may
shed further light on the role of particular exposures, including
infections, in this process. Tropical populations may be at high
risk for atopic ARD if and when such protective exposures are
removed.
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Supporting Information
Additional Supporting Information may be found in the online version of
this article:
Table S1. Longitudinal associations between reported ARD events or atopy
(SPT) in the first three years of life and reported ART events or atopy at age
nine years among children in the Entebbe Mother and Baby Study birth
cohort.
Table S2. Association between events (doctor diagnosed or reported recent)
early in life or atopy early in life, and doctor-diagnosed events between age
five and nine years among children in the Entebbe Mother and Baby Study
birth cohort.
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